Prospects for polymer therapeutics in Parkinson's disease and other neurodegenerative disorders

Progress in Polymer Science

Volumn 44, Issue , 2015, Pages 79-112

  Newland, Ben ^a,b   Newland, Heike ^b   Werner, Carsten ^b,c   Rosser, Anne ^a   Wang, Wenxin ^d,e  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b LEIBNIZ INSTITUTE OF POLYMER RESEARCH DRESDEN   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

^e TIANJIN UNIVERSITY   (China)

Author keywords

Cell therapies; Controlled release; Drug delivery; Gene delivery; Growth factors; Transfection

Indexed keywords

BIOSYNTHESIS; CONTROLLED DRUG DELIVERY; DISEASES; DRUG DELIVERY; DRUG THERAPY; FUNCTIONAL POLYMERS; GENE THERAPY; GENE TRANSFER; MOLECULAR BIOLOGY; NEURONS; POLYMERS; SYNTHESIS (CHEMICAL);

CELL THERAPY; CONTROLLED RELEASE; GENE DELIVERY; GROWTH FACTOR; TRANSFECTION;

NEURODEGENERATIVE DISEASES;

EID: 84939995837     PISSN: 00796700     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.progpolymsci.2014.12.002     Document Type: Review

References (330)

1. C.D. Marsden, and J.D. Parkes Success and problems of long-term levodopa therapy in Parkinson's disease Lancet 309 1977 345 349
2. M.C. Kiernan, S. Vucic, B.C. Cheah, M.R. Turner, A. Eisen, O. Hardiman, J.R. Burrell, and M.C. Zoing Amyotrophic lateral sclerosis Lancet 377 2011 942 955
3. W. Poewe The natural history of Parkinson's disease J Neurol 253 2006 vii2 vii6
4. J.M. Fearnley, and A.J. Lees Ageing and Parkinson's disease: substantia nigra regional selectivity Brain 114 1991 2283 2301
5. I.E. Donaghue, R. Tam, M.V. Sefton, and M.S. Shoichet Cell and biomolecule delivery for tissue repair and regeneration in the central nervous system J Control Release 190 2014 219 227
6. D.M. Gash, Z. Zhang, and G. Gerhardt Neuroprotective and neurorestorative properties of GDNF Ann Neurol 44 1998 S121 S125
7. A.L. Peterson, and J.G. Nutt Treatment of Parkinson's disease with trophic factors Neurotherapeutics 5 2008 270 280
8. L. Aron, and R. Klein Repairing the parkinsonian brain with neurotrophic factors Trends Neurosci 34 2011 88 100
9. T. Rodrigues, A. Jerónimo-Santos, T. Outeiro, A. Sebastião, and M. Diógenes Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease Drugs Aging 31 2014 239 261
10. J.H. Kordower, and A. Bjorklund Trophic factor gene therapy for Parkinson's disease Mov Disord 28 2013 96 109
11. N.K. Mohtaram, A. Montgomery, and S.M. Willerth Biomaterial-based drug delivery systems for the controlled release of neurotrophic factors Biomed Mater 8 2013 022001/1-13
12. M.K. Nguyen, and E. Alsberg Bioactive factor delivery strategies from engineered polymer hydrogels for therapeutic medicine Prog Polym Sci 39 2014 1235 1265
13. A. Nunes, K.T. Al-Jamal, and K. Kostarelos Therapeutics, imaging and toxicity of nanomaterials in the central nervous system J Control Release 161 2012 290 306
14. M. Breunig, U. Lungwitz, R. Liebl, and A. Goepferich Breaking up the correlation between efficacy and toxicity for nonviral gene delivery Proc Natl Acad Sci U S A 104 2007 14454 14459
15. D.B. Hoban, B. Newland, T.C. Moloney, L. Howard, A. Pandit, and E. Dowd The reduction in immunogenicity of neurotrophin overexpressing stem cells after intra-striatal transplantation by encapsulation in an in situ gelling collagen hydrogel Biomaterials 34 2013 9420 9429
16. B. Newland, T.C. Moloney, G. Fontana, S. Browne, M.T. Abu-Rub, E. Dowd, and A.S. Pandit The neurotoxicity of gene vectors and its amelioration by packaging with collagen hollow spheres Biomaterials 34 2013 2130 2141
17. P.S. Manoonkitiwongsa, C. Jackson-Friedman, P.J. McMillan, R.L. Schultz, and P.D. Lyden Angiogenesis after stroke is correlated with increased numbers of macrophages: the clean-up hypothesis J Cereb Blood Flow Metab 21 2001 1223 1231
18. J.W. Fawcett, and R.A. Asher The glial scar and central nervous system repair Brain Res Bull 49 1999 377 391
19. J. Silver, and J.H. Miller Regeneration beyond the glial scar Nat Rev Neurosci 5 2004 146 156
20. E. Preston, J. Webster, and D. Small Characteristics of sustained blood-brain barrier opening and tissue injury in a model for focal trauma in the rat J Neurotrauma 18 2001 83 92
21. E. Aurand, J. Wagner, C. Lanning, and K. Bjugstad Building biocompatible hydrogels for tissue engineering of the brain and spinal cord J Funct Biomater 3 2012 839 863
22. T. Nakaji-Hirabayashi, K. Kato, and H. Iwata Hyaluronic acid hydrogel loaded with genetically-engineered brain-derived neurotrophic factor as a neural cell carrier Biomaterials 30 2009 4581 4589
23. D. Emerich, D. Mooney, H. Storrie, R. Babu, and J. Kordower Injectable hydrogels providing sustained delivery of vascular endothelial growth factor are neuroprotective in a rat model of Huntington's disease Neurotox Res 17 2010 66 74
24. U. Freudenberg, A. Hermann, P.B. Welzel, K. Stirl, S.C. Schwarz, M. Grimmer, A. Zieris, W. Panyanuwat, S. Zschoche, D. Meinhold, A. Storch, and C. Werner A star-PEG-heparin hydrogel platform to aid cell replacement therapies for neurodegenerative diseases Biomaterials 30 2009 5049 5060
25. D.F. Emerich, E. Silva, O. Ali, D. Mooney, W. Bell, S.J. Yu, Y. Kaneko, and C. Borlongan Injectable VEGF hydrogels produce near complete neurological and anatomical protection following cerebral ischemia in rats Cell Transpl 19 2010 1063 1071
26. E.J. Bradbury, L.D.F. Moon, R.J. Popat, V.R. King, G.S. Bennett, P.N. Patel, J.W. Fawcett, and S.B. McMahon Chondroitinase ABC promotes functional recovery after spinal cord injury Nature 416 2002 636 640
27. R.R. Zhao, and J. Fawcett Combination treatment with chondroitinase ABC in spinal cord injury - breaking the barrier Neurosci Bull 29 2013 477 483
28. F. Cicchetti, and R.A. Barker The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue? Front Pharmacol 5 2014 00139/1-11
29. C. de Rham, V. Tieng, B. Tournier, Y. Avila, and N. Ginovart The role of immunosuppression in the transplantation of allogenic neural precursors derived from human pluripotent stem cells for Parkinson's disease J Stem Cell Res Ther S6 6 2013 1 9
30. M. Hovakimyan, J. Müller, A. Wree, S. Ortinau, A. Rolfs, and O. Schmitt Survival of transplanted human neural stem cell line (ReNcell VM) into the rat brain with and without immunosuppression Ann Anat 194 2012 429 435
31. M. Janowski, C. Engels, M. Gorelik, A. Lyczek, S. Bernard, J. Bulte, and P. Walczak Survival of neural progenitors allografted into the CNS of immunocompetent recipients is highly dependent on transplantation site Cell Transpl 23 2014 253 262
32. M. Ideguchi, M. Shinoyama, M. Gomi, H. Hayashi, N. Hashimoto, and J. Takahashi Immune or inflammatory response by the host brain suppresses neuronal differentiation of transplanted ES cell-derived neural precursor cells J Neurosci Res 86 2008 1936 1943
33. R.A. Barker, and H. Widner Immune problems in central nervous system cell therapy NeuroRX 1 2004 472 481
34. T. Nakaji-Hirabayashi, and H. Kitano Interleukin-10 chimeric protein to protect transplanted neural progenitor cells from immune responses J Mater Chem B 2 2014 8598 8607
35. D. Velasco, G. Réthoré, B. Newland, J. Parra, C. Elvira, A. Pandit, L. Rojo, and J.S. Román Low polydispersity (N-ethyl pyrrolidine methacrylamide-co-1-vinylimidazole) linear oligomers for gene therapy applications Eur J Pharm Biopharm 82 2012 465 474
36. C.F. Jones, R.A. Campbell, A.E. Brooks, S. Assemi, S. Tadjiki, G. Thiagarajan, C. Mulcock, A.S. Weyrich, B.D. Brooks, H. Ghandehari, and D.W. Grainger Cationic PAMAM dendrimers aggressively initiate blood clot formation ACS Nano 6 2012 9900 9910
37. W. Wang, W. Xiong, Y. Zhu, H. Xu, and X. Yang Protective effect of PEGylation against poly(amidoamine) dendrimer-induced hemolysis of human red blood cells J Biomed Mater Res Part B 93 2010 59 64
38. R. Huang, W. Ke, Y. Liu, C. Jiang, and Y. Pei The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain Biomaterials 29 2008 238 246
39. M.E. Jönhagen, A. Nordberg, K. Amberla, L. Bäckman, T. Ebendal, B. Meyerson, L. Olson, Å. Seiger, M. Shigeta, E. Theodorsson, M. Viitanen, B. Winblad, and L.O. Wahlund Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease Dement Geriatr Cogn Disord 9 1998 246 257
40. J. Winkler, G.A. Ramirez, H.G. Kuhn, D.A. Peterson, P.A. Day-Lollini, G.R. Stewart, M.H. Tuszynski, F.H. Gage, and L.J. Thal Reversible Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor Ann Neurol 41 1997 82 93
41. M. Eriksdotter-Jönhagen, B. Linderoth, G. Lind, L. Aladellie, O. Almkvist, N. Andreasen, K. Blennow, N. Bogdanovic, V. Jelic, A. Kadir, A. Nordberg, E. Sundström, L.O. Wahlund, A. Wall, M. Wiberg, B. Winblad, Å. Seiger, P. Almqvist, and L. Wahlberg Encapsulated cell biodelivery of nerve growth factor to the basal forebrain in patients with Alzheimer's disease Dement Geriatr Cogn Disord 33 2012 18 28
42. D.F. Emerich, G. Orive, C. Thanos, J. Tornoe, and L.U. Wahlberg Encapsulated cell therapy for neurodegenerative diseases: from promise to product Adv Drug Deliv Rev 67-68 2014 131 141
43. L.U. Wahlberg, G. Lind, P.M. Almqvist, P. Kusk, J. Tornoe, B. Juliusson, M. Söderman, E. Selldén, Å. Seiger, M. Eriksdotter-Jönhagen, and B. Linderoth Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery J Neurosurg 117 2012 340 347
44. C. Haberler, F. Alesch, P.R. Mazal, P. Pilz, K. Jellinger, M.M. Pinter, J.A. Hainfellner, and H. Budka No tissue damage by chronic deep brain stimulation in Parkinson's disease Ann Neurol 48 2000 372 376
45. J.M. Henderson, M. Pell, D.J. O'Sullivan, E.A. McCusker, V.S.C. Fung, P. Hedges, and G.M. Halliday Postmortem analysis of bilateral subthalamic electrode implants in Parkinson's disease Mov Disord 17 2002 133 137
46. K.B. Bjugstad, K. Lampe, D.S. Kern, and M. Mahoney Biocompatibility of poly(ethylene glycol)-based hydrogels in the brain: an analysis of the glial response across space and time J Biomed Mater Res Part A 95 2010 79 91
47. D. Jgamadze, J. Bergen, D. Stone, J.H. Jang, D.V. Schaffer, E.Y. Isacoff, and S. Pautot Colloids as mobile substrates for the implantation and integration of differentiated neurons into the mammalian brain PLoS ONE 7 2012 e30293/1-11
48. B.D. Ulery, L.S. Nair, and C.T. Laurencin Biomedical applications of biodegradable polymers J Polym Sci B: Polym Phys 49 2011 832 864
49. T.G. Park Degradation of poly(d,l-lactic acid) microspheres: effect of molecular weight J Control Release 30 1994 161 173
50. J.M. Anderson, and M.S. Shive Biodegradation and biocompatibility of PLA and PLGA microspheres Adv Drug Deliv Rev 64 2012 72 82
51. Y. Li, J. Rodrigues, and H. Tomas Injectable and biodegradable hydrogels: gelation, biodegradation and biomedical applications Chem Soc Rev 41 2012 2193 2221
52. M. Prewitz, F.P. Seib, T. Pompe, and C. Werner Polymeric biomaterials for stem cell bioengineering Macromol Rapid Commun 33 2012 1420 1431
53. F.Z. Cui, W.M. Tian, S.P. Hou, Q.Y. Xu, and I.S. Lee Hyaluronic acid hydrogel immobilized with RGD peptides for brain tissue engineering J Mater Sci Mater Med 17 2006 1393 1401
54. W.M. Tian, S.P. Hou, J. Ma, C.L. Zhang, Q.Y. Xu, I.S. Lee, H.D. Li, M. Spector, and F.Z. Cui Hyaluronic acid-poly-d-lysine-based three-dimensional hydrogel for traumatic brain injury Tissue Eng Part A 11 2005 513 525
55. M.V. Tsurkan, K. Chwalek, K.R. Levental, U. Freudenberg, and C. Werner Modular star-PEG-heparin gels with bifunctional peptide linkers Macromol Rapid Commun 31 2010 1529 1533
56. M.V. Tsurkan, P.V. Hauser, A. Zieris, R. Carvalhosa, B. Bussolati, U. Freudenberg, G. Camussi, and C. Werner Growth factor delivery from hydrogel particle aggregates to promote tubular regeneration after acute kidney injury J Control Release 167 2013 248 255
57. S. Browne, G. Fontana, B.J. Rodriguez, and A. Pandit A protective extracellular matrix-based gene delivery reservoir fabricated by electrostatic charge manipulation Mol Pharm 9 2012 3099 3106
58. P.B. Welzel, M. Grimmer, C. Renneberg, L. Naujox, S. Zschoche, U. Freudenberg, and C. Werner Macroporous star-PEG-heparin cryogels Biomacromolecules 13 2012 2349 2358
59. M.V. Tsurkan, K. Chwalek, S. Prokoph, A. Zieris, K.R. Levental, U. Freudenberg, and C. Werner Defined polymer-peptide conjugates to form cell-instructive star-PEG-heparin matrices in situ Adv Mater 25 2013 2606 2610
60. E.R. Aurand, K.J. Lampe, and K.B. Bjugstad Defining and designing polymers and hydrogels for neural tissue engineering Neurosci Res 72 2012 199 213
61. O. Sarig-Nadir, and D. Seliktar The role of matrix metalloproteinases in regulating neuronal and nonneuronal cell invasion into PEGylated fibrinogen hydrogels Biomaterials 31 2010 6411 6416
62. J. Patterson, and J.A. Hubbell Enhanced proteolytic degradation of molecularly engineered PEG hydrogels in response to MMP-1 and MMP-2 Biomaterials 31 2010 7836 7845
63. N.J. Abbott, A.A.K. Patabendige, D.E.M. Dolman, S.R. Yusof, and D.J. Begley Structure and function of the blood-brain barrier Neurobiol Dis 37 2010 13 25
64. H. Wei, R.X. Zhuo, and X.Z. Zhang Design and development of polymeric micelles with cleavable links for intracellular drug delivery Prog Polym Sci 38 2013 503 535
65. S.E. Paramonov, E.M. Bachelder, T.T. Beaudette, S.M. Standley, C.C. Lee, J. Dashe, and J.M.J. Fréchet Fully acid-degradable biocompatible polyacetal microparticles for drug delivery Bioconjugate Chem 19 2008 911 919
66. Y. Zheng, H. Cao, B. Newland, Y. Dong, A. Pandit, and W. Wang 3D single cyclized polymer chain structure from controlled polymerization of multi-vinyl monomers: beyond Flory-Stockmayer theory J Am Chem Soc 133 2011 13130 13137
67. Y. Zheng, B. Newland, H. Tai, A. Pandit, and W. Wang Single cyclized molecule structures from RAFT homopolymerization of multi-vinyl monomers Chem Commun 48 2012 3085 3087
68. F.J. Xu, and W.T. Yang Polymer vectors via controlled/living radical polymerization for gene delivery Prog Polym Sci 36 2011 1099 1131
69. D.S.H. Chu, J.G. Schellinger, J. Shi, A.J. Convertine, P.S. Stayton, and S.H. Pun Application of living free radical polymerization for nucleic acid delivery Acc Chem Res 45 2012 1089 1099
70. C.V. Synatschke, A. Schallon, V. Jérôme, R. Freitag, and A.H.E. Müller Influence of polymer architecture and molecular weight of poly(2-(dimethylamino)ethyl methacrylate) polycations on transfection efficiency and cell viability in gene delivery Biomacromolecules 12 2011 4247 4255
71. B. Newland, Y. Zheng, Y. Jin, M. Abu-Rub, H. Cao, W. Wang, and A. Pandit Single cyclized molecule versus single branched molecule: a simple and efficient 3D "knot" polymer structure for nonviral gene delivery J Am Chem Soc 134 2012 4782 4789
72. S. Son, D.W. Hwang, K. Singha, J.H. Jeong, T.G. Park, D.S. Lee, and W.J. Kim RVG peptide tethered bioreducible polyethylenimine for gene delivery to brain J Control Release 155 2011 18 25
73. D.W. Hwang, S. Son, J. Jang, H. Youn, S. Lee, D. Lee, Y.S. Lee, J.M. Jeong, W.J. Kim, and D.S. Lee A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA Biomaterials 32 2011 4968 4975
74. M. Keeney, S.G. Ong, A. Padilla, Z. Yao, S. Goodman, J.C. Wu, and F. Yang Development of poly(β-amino ester)-based biodegradable nanoparticles for nonviral delivery of minicircle DNA ACS Nano 7 2013 7241 7250
75. S.Y. Tzeng, H. Guerrero-Cázares, E.E. Martinez, J.C. Sunshine, A. Quiñones-Hinojosa, and J.J. Green Non-viral gene delivery nanoparticles based on poly(β-amino esters) for treatment of glioblastoma Biomaterials 32 2011 5402 5410
76. A.C. Fonseca, M.H. Gil, and P.N. Simões Biodegradable poly(ester amide)s - a remarkable opportunity for the biomedical area: review on the synthesis, characterization and applications Prog Polym Sci 39 2014 1291 1311
77. S.Y. Tzeng, and J.J. Green Subtle changes to polymer structure and degradation mechanism enable highly effective nanoparticles for siRNA and DNA delivery to human brain cancer Adv Healthc Mater 2 2013 468 480
78. B. Newland, A. Aied, A. Pinoncely, Y. Zheng, T. Zhao, H. Zhang, R. Niemeier, E. Dowd, A. Pandit, and W. Wang Untying a nanoscale knotted polymer structure to linear chains for efficient gene delivery in vitro and to the brain Nanoscale 6 2014 7526 7533
79. J. Shi, R.N. Johnson, J.G. Schellinger, P.M. Carlson, and S.H. Pun Reducible HPMA-co-oligolysine copolymers for nucleic acid delivery Int J Pharm 427 2012 113 122
80. H. Zhang, and S.V. Vinogradov Short biodegradable polyamines for gene delivery and transfection of brain capillary endothelial cells J Control Release 143 2010 359 366
81. C. Chapman, W. Frey II, S. Craft, L. Danielyan, M. Hallschmid, H. Schiöth, and C. Benedict Intranasal treatment of central nervous system dysfunction in humans Pharmaceut Res 30 2013 2475 2484
82. N.U. Barua, K. Hopkins, M. Woolley, S. O'Sullivan, R. Harrison, R.J. Edwards, A.S. Bienemann, M.J. Wyatt, A. Arshad, and S.S. Gill A novel implantable catheter system with transcutaneous port for intermittent convection-enhanced delivery of carboplatin for recurrent glioblastoma Drug Deliv 2015 [in press]
83. N.U. Barua, S.S. Gill, and S. Love Convection-enhanced drug delivery to the brain: therapeutic potential and neuropathological considerations Brain Pathol 24 2014 117 127
84. N.U. Barua, A.S. Bienemann, S. Hesketh, M.J. Wyatt, E. Castrique, S. Love, and S.S. Gill Intrastriatal convection-enhanced delivery results in widespread perivascular distribution in a pre-clinical model Fluids Barriers CNS 9 2012 2/1-12
85. B.T. Harmon, A.E. Aly, L. Padegimas, O. Sesenoglu-Laird, M.J. Cooper, and B.L. Waszczak Intranasal administration of plasmid DNA nanoparticles yields successful transfection and expression of a reporter protein in rat brain Gene Ther 21 2014 514 521
86. B.S. Bleier, R.E. Kohman, R.E. Feldman, S. Ramanlal, and X. Han Permeabilization of the blood-brain barrier via mucosal engrafting: implications for drug delivery to the brain PLoS ONE 8 2013 e61694/1-7
87. A. Burgess, C.A. Ayala-Grosso, M. Ganguly, J.F. Jordão, I. Aubert, and K. Hynynen Targeted delivery of neural stem cells to the brain using MRI-guided focused ultrasound to disrupt the blood-brain barrier PLoS ONE 6 2011 e27877/1-6
88. B. Newland, E. Dowd, and A. Pandit Biomaterial approaches to gene therapies for neurodegenerative disorders of the CNS Biomater Sci 1 2013 556 576
89. I.K. Park, J. Lasiene, S.H. Chou, P.J. Horner, and S.H. Pun Neuron-specific delivery of nucleic acids mediated by Tet1-modified poly(ethylenimine) J Gene Med 9 2007 691 702
90. E.J. Kwon, J. Lasiene, B.E. Jacobson, I.K. Park, P.J. Horner, and S.H. Pun Targeted nonviral delivery vehicles to neural progenitor cells in the mouse subventricular zone Biomaterials 31 2010 2417 2424
91. M.J. Writer, P.G. Kyrtatos, A.S. Bienemann, J.A. Pugh, A.S. Lowe, C. Villegas-Llerena, G.D. Kenny, E.A. White, S.S. Gill, C.W. McLeod, M.F. Lythgoe, and S.L. Hart Lipid peptide nanocomplexes for gene delivery and magnetic resonance imaging in the brain J Control Release 162 2012 340 348
92. W. Wang, Y. Zheng, E. Roberts, C.J. Duxbury, L. Ding, D.J. Irvine, and S.M. Howdle Controlling chain growth: a new strategy to hyperbranched materials Macromolecules 40 2007 7184 7194
93. S.C. Harrison Looking inside adenovirus Science 329 2010 1026 1027
94. V.S. Reddy, S.K. Natchiar, P.L. Stewart, and G.R. Nemerow Crystal structure of human adenovirus at 3.5 A resolution Science 329 2010 1071 1075
95. H. Liu, L. Jin, S.B.S. Koh, I. Atanasov, S. Schein, L. Wu, and Z.H. Zhou Atomic structure of human adenovirus by cryo-EM reveals interactions among protein networks Science 329 2010 1038 1043
96. B. Newland, M. Abu-Rub, M. Naughton, Y. Zheng, A.V. Pinoncely, E. Collin, E. Dowd, W. Wang, and A. Pandit GDNF gene delivery via a 2-(dimethylamino)ethyl methacrylate based cyclized knot polymer for neuronal cell applications ACS Chem Neurosci 4 2013 540 546
97. B. Newland, H. Tai, Y. Zheng, D. Velasco, A.D. Luca, S.M. Howdle, C. Alexander, W. Wang, and A. Pandit A highly effective gene delivery vector - hyperbranched poly(2-(dimethylamino)ethyl methacrylate) from in situ deactivation enhanced ATRP Chem Commun 46 2010 4698 4700
98. M. Monaghan, U. Greiser, H. Cao, W. Wang, and A. Pandit An antibody fragment functionalized dendritic PEGylated poly(2-(dimethylamino)ethyl diacrylate) as a vehicle of exogenous microRNA Drug Deliv Transl Res 2 2012 406 414
99. H. Ding, S. Inoue, A.V. Ljubimov, R. Patil, J. Portilla-Arias, J. Hu, B. Konda, K.A. Wawrowsky, M. Fujita, N. Karabalin, T. Sasaki, K.L. Black, E. Holler, and J.Y. Ljubimova Inhibition of brain tumor growth by intravenous poly(β-l-malic acid) nanobioconjugate with pH-dependent drug release Proc Natl Acad Sci U S A 107 2010 18143 18148
100. H. Gao, Z. Pang, and X. Jiang Targeted delivery of nano-therapeutics for major disorders of the central nervous system Pharmaceut Res 30 2013 2485 2498
101. Y. Liu, R. Huang, and C. Jiang Non-viral gene delivery and therapeutics targeting to brain Curr Nanosci 7 2011 55 70
102. T. Kanazawa, H. Taki, K. Tanaka, Y. Takashima, and H. Okada Cell-penetrating peptide-modified block copolymer micelles promote direct brain delivery via intranasal administration Pharmaceut Res 28 2011 2130 2139
103. T. Kanazawa, F. Akiyama, S. Kakizaki, Y. Takashima, and Y. Seta Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles Biomaterials 34 2013 9220 9226
104. Z. Wen, Z. Yan, K. Hu, Z. Pang, X. Cheng, L. Guo, Q. Zhang, X. Jiang, L. Fang, and R. Lai Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration J Control Release 151 2011 131 138
105. H. Xia, X. Gao, G. Gu, Z. Liu, N. Zeng, Q. Hu, Q. Song, L. Yao, Z. Pang, X. Jiang, J. Chen, and H. Chen Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration Biomaterials 32 2011 9888 9898
106. W.A. Jefferies, M.R. Brandon, S.V. Hunt, A.F. Williams, K.C. Gatter, and D.Y. Mason Transferrin receptor on endothelium of brain capillaries Nature 312 1984 162 163
107. K. Ulbrich, T. Hekmatara, E. Herbert, and J. Kreuter Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB) Eur J Pharm Biopharm 71 2009 251 256
108. C. Dufès, M.A. Robaian, and S. Somani Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells Ther Deliv 4 2013 629 640
109. N. Shi, and W.M. Pardridge Noninvasive gene targeting to the brain Proc Natl Acad Sci U S A 97 2000 7567 7572
110. M.T. Girao da Cruz, A.L.C. Cardoso, L.P. de Almeida, S. Simoes, and M.C. Pedroso de Lima Tf-lipoplex-mediated NGF gene transfer to the CNS: neuronal protection and recovery in an excitotoxic model of brain injury Gene Ther 12 2005 1242 1252
111. A.L.C. Cardoso, S. Simões, L.P. de Almeida, N. Plesnila, M.C. Pedroso de Lima, E. Wagner, and C. Culmsee Tf-lipoplexes for neuronal siRNA delivery: a promising system to mediate gene silencing in the CNS J Control Release 132 2008 113 123
112. A.L.C. Cardoso, P. Costa, L.P. Almeida, S. Simões, N. Plesnila, C. Culmsee, E. Wagner, and M.C. Pedroso de Lima Tf-lipoplex-mediated c-Jun silencing improves neuronal survival following excitotoxic damage in vivo J Control Release 142 2010 392 403
113. H. Zhao, G.L. Li, R.Z. Wang, S.F. Li, J.J. Wei, M. Feng, Y.J. Zhao, W.B. Ma, Y. Yang, Y.N. Li, and Y.G. Kong A comparative study of transfection efficiency between liposomes, immunoliposomes and brain-specific immunoliposomes J Int Med Res 38 2010 957 966
114. I. van Rooy, E. Mastrobattista, G. Storm, W.E. Hennink, and R.M. Schiffelers Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain J Control Release 150 2011 30 36
115. A. Srivastava, I.B. O'Connor, A. Pandit, and J.G. Wall Polymer-antibody fragment conjugates for biomedical applications Prog Polym Sci 39 2013 308 329
116. J.Y. Kim, W.I. Choi, Y.H. Kim, and G. Tae Brain-targeted delivery of protein using chitosan- and RVG peptide-conjugated, pluronic-based nano-carrier Biomaterials 34 2013 1170 1178
117. Y. Liu, R. Huang, L. Han, W. Ke, K. Shao, L. Ye, J. Lou, and C. Jiang Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles Biomaterials 30 2009 4195 4202
118. Y. Liu, Y. Guo, S. An, Y. Kuang, X. He, H. Ma, J. Li, J. Lv, N. Zhang, and C. Jiang Targeting caspase-3 as dual therapeutic benefits by RNAi facilitating brain-targeted nanoparticles in a rat model of Parkinson's disease PLoS ONE 8 2013 e62905/1-12
119. R. Huang, L. Han, J. Li, F. Ren, W. Ke, C. Jiang, and Y. Pei Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles J Gene Med 11 2009 754 763
120. R. Huang, W. Ke, L. Han, Y. Liu, K. Shao, C. Jiang, and Y. Pei Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo Brain Res Bull 81 2010 600 604
121. J. Li, L. Feng, L. Fan, Y. Zha, L. Guo, Q. Zhang, J. Chen, Z. Pang, Y. Wang, X. Jiang, V.C. Yang, and L. Wen Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides Biomaterials 32 2011 4943 4950
122. Y. Qian, Y. Zha, B. Feng, Z. Pang, B. Zhang, X. Sun, J. Ren, C. Zhang, X. Shao, Q. Zhang, and X. Jiang PEGylated poly(2-(dimethylamino) ethyl methacrylate)/DNA polyplex micelles decorated with phage-displayed TGN peptide for brain-targeted gene delivery Biomaterials 34 2013 2117 2129
123. J. Li, C. Zhang, J. Li, L. Fan, X. Jiang, J. Chen, Z. Pang, and Q. Zhang Brain delivery of NAP with PEG-PLGA nanoparticles modified with phage display peptides Pharmaceut Res 30 2013 1813 1823
124. B. Meloni, A. Craig, N. Milech, R. Hopkins, P. Watt, and N. Knuckey The neuroprotective efficacy of cell-penetrating peptides TAT, penetratin, Arg-9, and Pep-1 in glutamic acid, kainic acid, and in vitro ischemia injury models using primary cortical neuronal cultures Cell Mol Neurobiol 34 2014 173 181
125. Y. Miura, T. Takenaka, K. Toh, S. Wu, H. Nishihara, M.R. Kano, Y. Ino, T. Nomoto, Y. Matsumoto, H. Koyama, H. Cabral, N. Nishiyama, and K. Kataoka Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier ACS Nano 7 2013 8583 8592
126. S. Ohshima-Hosoyama, H.A. Simmons, N. Goecks, V. Joers, C.R. Swanson, V. Bondarenko, R. Velotta, K. Brunner, L.D. Wood, R.H. Hruban, and M.E. Emborg A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeys PLoS ONE 7 2012 e39036/1-14
127. A. Drinkut, Y. Tereshchenko, J.B. Schulz, M. Bahr, and S. Kugler Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery Mol Ther 20 2012 534 543
128. Y. Zhang, and W. Pardridge Near complete rescue of experimental Parkinson's disease with intravenous, non-viral GDNF gene therapy Pharmaceut Res 26 2009 1059 1063
129. C.F. Xia, R.J. Boado, Y. Zhang, C. Chu, and W.M. Pardridge Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter J Gene Med 10 2008 306 315
130. A. Kowalczuk, R. Trzcinska, B. Trzebicka, A.H.E. Müller, A. Dworak, and C.B. Tsvetanov Loading of polymer nanocarriers: factors, mechanisms and applications Prog Polym Sci 39 2014 43 86
131. S.S. Parelkar, D. Chan-Seng, and T. Emrick Reconfiguring polylysine architectures for controlling polyplex binding and non-viral transfection Biomaterials 32 2011 2432 2444
132. C. Tu, N. Li, L. Zhu, L. Zhou, Y. Su, P. Li, and X. Zhu Cationic long-chain hyperbranched poly(ethylene glycol)s with low charge density for gene delivery Polym Chem 4 2013 393 401
133. R. Censi, T. Vermonden, H. Deschout, K. Braeckmans, P. di Martino, S.C. De Smedt, C.F. van Nostrum, and W.E. Hennink Photopolymerized thermosensitive poly(HPMAlactate)-PEG-based hydrogels: effect of network design on mechanical properties, degradation, and release behavior Biomacromolecules 11 2010 2143 2151
134. H. Gao, and K. Matyjaszewski Synthesis of functional polymers with controlled architecture by CRP of monomers in the presence of cross-linkers: from stars to gels Prog Polym Sci 34 2009 317 350
135. W.A. Braunecker, and K. Matyjaszewski Controlled/living radical polymerization: features, developments and perspectives Prog Polym Sci 32 2007 93 146
136. K. Milowska, M. Malachowska, and T. Gabryelak PAMAM G4 dendrimers affect the aggregation of α-synuclein Int J Biol Macromol 48 2011 742 746
137. L.S. Nair, and C.T. Laurencin Biodegradable polymers as biomaterials Prog Polym Sci 32 2007 762 798
138. M. Ahmed, and R. Narain Progress of RAFT based polymers in gene delivery Prog Polym Sci 38 2013 767 790
139. L. Wightman, R. Kircheis, V. Rössler, S. Carotta, R. Ruzicka, M. Kursa, and E. Wagner Different behavior of branched, linear polyethylenimine for gene delivery in vitro and in vivo J Gene Med 3 2001 362 372
140. J.W. Wiseman, C.A. Goddard, D. McLelland, and W.H. Colledge A comparison of linear and branched polyethylenimine (PEI) with DCChol//DOPE liposomes for gene delivery to epithelial cells in vitro and in vivo Gene Ther 10 2003 1654 1662
141. A. Schallon, V. Jérôme, A. Walther, C.V. Synatschke, A.H.E. Müller, and R. Freitag Performance of three PDMAEMA-based polycation architectures as gene delivery agents in comparison to linear and branched PEI React Func Polym 70 2010 1 10
142. D.A. Tomalia, A.M. Naylor, and W.A. Goddard Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter Angew Chem Int Ed 29 1990 138 175
143. S. Svenson, and D.A. Tomalia Dendrimers in biomedical applications - reflections on the field Adv Drug Deliv Rev 64 2012 102 115
144. Y. Li, and S.P. Armes Synthesis of model primary amine-based branched copolymers by pseudo-living radical copolymerization and post-polymerization coupling of homopolymers Macromolecules 42 2009 939 945
145. 1H NMR spectroscopy Macromolecules 45 2012 2731 2737
146. M.L. Koh, D. Konkolewicz, and S.B. Perrier A simple route to functional highly branched structures: RAFT homopolymerization of divinylbenzene Macromolecules 44 2011 2715 2724
147. K. Matyjaszewski, and J. Xia Atom transfer radical polymerization Chem Rev 101 2001 2921 2990
148. D.J. Siegwart, J.K. Oh, and K. Matyjaszewski ATRP in the design of functional materials for biomedical applications Prog Polym Sci 37 2012 18 37
149. H. Gao, and K. Matyjaszewski Synthesis of star polymers by a new "core-first" method: sequential polymerization of cross-linker and monomer Macromolecules 41 2008 1118 1125
150. T. Zhao, Y. Zheng, J. Poly, and W. Wang Controlled multi-vinyl monomer homopolymerization through vinyl oligomer combination as a universal approach to hyperbranched architectures Nat Commun 4 2013 1873
151. A.V. Kabanov, and S.V. Vinogradov Nanogels as pharmaceutical carriers: finite networks of infinite capabilities Angew Chem Int Ed 48 2009 5418 5429
152. J.K. Oh, R. Drumright, D.J. Siegwart, and K. Matyjaszewski The development of microgels/nanogels for drug delivery applications Prog Polym Sci 33 2008 448 477
153. B. Lanfer, A. Hermann, M. Kirsch, U. Freudenberg, U. Reuner, C. Werner, and A. Storch Directed growth of adult human white matter stem cell-derived neurons on aligned fibrillar collagen Tissue Eng Part A 16 2009 1103 1113
154. T.Y. Wang, K.A.F. Bruggeman, R.K. Sheean, B.J. Turner, D.R. Nisbet, and C.L. Parish Characterisation of the stability and bio-functionality of tethered proteins on bioengineered scaffolds: implications for stem cell biology and tissue repair J Biol Chem 289 2014 15044 15051
155. C.L. Lau, M. Kovacevic, T.S. Tingleff, J.S. Forsythe, H.S. Cate, D. Merlo, C. Cederfur, F.L. Maclean, C.L. Parish, M.K. Horne, D.R. Nisbet, and P.M. Beart 3D electrospun scaffolds promote a cytotrophic phenotype of cultured primary astrocytes J Neurochem 130 2014 215 226
156. T. Wang, J. Forsythe, C. Parish, and D. Nisbet Biofunctionalisation of polymeric scaffolds for neural tissue engineering J Biomater Appl 27 2012 369 390
157. A.O. Saeed, B. Newland, A. Pandit, and W. Wang The reverse of polymer degradation: in situ crosslinked gel formation through disulfide cleavage Chem Commun 48 2012 585 587
158. S.A. Bencherif, R.W. Sands, D. Bhatta, P. Arany, C.S. Verbeke, D.A. Edwards, and D.J. Mooney Injectable preformed scaffolds with shape-memory properties Proc Natl Acad Sci U S A 109 2012 19590 19595
159. M. Guvendiren, H.D. Lu, and J.A. Burdick Shear-thinning hydrogels for biomedical applications Soft Matter 8 2012 260 272
160. D.Y. Ko, U.P. Shinde, B. Yeon, and B. Jeong Recent progress of in situ formed gels for biomedical applications Prog Polym Sci 38 2013 672 701
161. Y. Dong, P. Gunning, H. Cao, A. Mathew, B. Newland, A.O. Saeed, J.P. Magnusson, C. Alexander, H. Tai, A. Pandit, and W. Wang Dual stimuli responsive PEG based hyperbranched polymers Polym Chem 1 2010 827 830
162. X. Chen, F. Zhi, X. Jia, X. Zhang, R. Ambardekar, Z. Meng, A.R. Paradkar, Y. Hu, and Y. Yang Enhanced brain targeting of curcumin by intranasal administration of a thermosensitive poloxamer hydrogel J Pharm Pharmacol 65 2013 807 816
163. R. Soto-Otero, E. Méndez-Álvarez, Á. Hermida-Ameijeiras, A.M. Muñoz-Patiño, and J.L. Labandeira-Garcia Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants J Neurochem 74 2000 1605 1612
164. E. Sofic, K.W. Lange, K. Jellinger, and P. Riederer Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease Neurosci Lett 142 1992 128 130
165. H. Saggu, J. Cooksey, D.A. Dexter, F.R. Wells, A. Lees, P. Jenner, and C.D. Marsden A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra J Neurochem 53 1989 692 697
166. P. Jenner, D.T. Dexter, J. Sian, A.H.V. Schapira, and C.D. Marsden Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease Ann Neurol 32 1992 S82 S87
167. S.J. Kish, K. Shannak, and O. Hornykiewicz Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease N Engl J Med 318 1988 876 880
168. P.A. LeWitt Levodopa for the treatment of Parkinson's disease N Engl J Med 359 2008 2468 2476
169. E. Needham, and P. Worth Parkinson's disease: a guide to pharmacological management Prescriber 23 2012 21 31
170. F. Stocchi, L. Vacca, S. Ruggieri, and C. Olanow Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study Archiv Neurol 62 2005 905 910
171. C.W. Olanow, J.A. Obeso, and F. Stocchi Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications Lancet Neurol 5 2006 677 687
172. P. Jenner Wearing off, dyskinesia, and the use of continuous drug delivery in Parkinson's disease Neurol Clin 31 2013 S17 S35
173. E. Garbayo, E. Ansorena, and M.J. Blanco-Prieto Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems Maturitas 76 2013 272 278
174. E. Garbayo, E. Ansorena, and M.J. Blanco-Prieto Brain drug delivery systems for neurodegenerative disorders Curr Pharm Biotechnol 13 2012 2388 2402
175. T. Patel, J. Zhou, J.M. Piepmeier, and W.M. Saltzman Polymeric nanoparticles for drug delivery to the central nervous system Adv Drug Deliv Rev 64 2012 701 705
176. A.V. Kabanov, and H.E. Gendelman Nanomedicine in the diagnosis and therapy of neurodegenerative disorders Prog Polym Sci 32 2007 1054 1082
177. E.D. Giglio, A. Trapani, D. Cafagna, L. Sabbatini, and S. Cometa Dopamine-loaded chitosan nanoparticles: formulation and analytical characterization Anal Bioanal Chem 400 2011 1997 2002
178. A. Trapani, E. De Giglio, D. Cafagna, N. Denora, G. Agrimi, T. Cassano, S. Gaetani, V. Cuomo, and G. Trapani Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery Int J Pharm 419 2011 296 307
179. M. Malhotra, C. Tomaro-Duchesneau, and S. Prakash Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases Biomaterials 34 2013 1270 1280
180. Y. Aktaş, M. Yemisci, K. Andrieux, R.N. Gürsoy, M.J. Alonso, E. Fernandez-Megia, R. Novoa-Carballal, E. Quiñoá, R. Riguera, M.F. Sargon, H.H. Çelik, A.S. Demir, A.A. HIncal, T. Dalkara, Y. Çapan, and P. Couvreur Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26 Bioconjugate Chem 16 2005 1503 1511
181. H. Karatas, Y. Aktas, Y. Gursoy-Ozdemir, E. Bodur, M. Yemisci, S. Caban, A. Vural, O. Pinarbasli, Y. Capan, E. Fernandez-Megia, R. Novoa-Carballal, R. Riguera, K. Andrieux, P. Couvreur, and T. Dalkara A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection J Neurosci 29 2009 13761 13769
182. E. D'Aurizio, C.F. van Nostrum, M.J. van Steenbergen, P. Sozio, F. Siepmann, J. Siepmann, W.E. Hennink, and A. diStefano Preparation and characterization of poly(lactic-co-glycolic acid) microspheres loaded with a labile antiparkinson prodrug Int J Pharm 409 2011 289 296
183. T. Ren, X. Yang, N. Wu, Y. Cai, Z. Liu, and W. Yuan Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats Neurosci Lett 502 2011 117 122
184. E. D'Aurizio, P. Sozio, L.S. Cerasa, M. Vacca, L. Brunetti, G. Orlando, A. Chiavaroli, R.J. Kok, W.E. Hennink, and A. Di Stefano Biodegradable microspheres loaded with an anti-Parkinson prodrug: an in vivo pharmacokinetic study Mol Pharm 8 2011 2408 2415
185. X. Yang, Y. Chen, X. Hong, N. Wu, L. Song, W. Yuan, and Z. Liu Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats Drug Des Dev Ther 6 2011 341 347
186. B. Ouattara, D. Hoyer, L. Grégoire, M. Morissette, F. Gasparini, B. Gomez-Mancilla, and T. Di Paolo Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias Neuroscience 167 2010 1160 1167
187. M. Decressac, A. Ulusoy, B. Mattsson, B. Georgievska, M. Romero-Ramos, D. Kirik, and A. Björklund GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease Brain 134 2011 2302 2311
188. P. Mulcahy, A. O'Doherty, A. Paucard, T. O'Brien, D. Kirik, and E. Dowd The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats Behav Brain Res 243 2013 6 15
189. D.B. Hoban, E. Connaughton, C. Connaughton, G. Hogan, C. Thornton, P. Mulcahy, T.C. Moloney, and E. Dowd Further characterisation of the LPS model of Parkinson's disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat Brain Behav Immun 27 2013 91 100
190. D. Kirik, L.E. Annett, C. Burger, N. Muzyczka, R.J. Mandel, and A. Björklund Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: a new primate model of Parkinson's disease Proc Natl Acad Sci U S A 100 2003 2884 2889
191. D. Ramonet, J.P.L. Daher, B.M. Lin, K. Stafa, J. Kim, R. Banerjee, M. Westerlund, O. Pletnikova, L. Glauser, L. Yang, Y. Liu, D.A. Swing, M.F. Beal, J.C. Troncoso, J.M. McCaffery, N.A. Jenkins, N.G. Copeland, D. Galter, B. Thomas, M.K. Lee, T.M. Dawson, V.L. Dawson, and D.J. Moore Dopaminergic neuronal loss reduced neurite complexity autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2 PLoS ONE 6 2011 e18568/1-15
192. T.M. Dawson, H.S. Ko, and V.L. Dawson Genetic animal models of Parkinson's disease Neuron 66 2010 646 661
193. E. Bezard, Z. Yue, D. Kirik, and M.G. Spillantini Animal models of Parkinson's disease: limits and relevance to neuroprotection studies Mov Disord 28 2013 61 70
194. C. Regnier-Delplace, O. Thillaye du Boullay, F. Siepmann, B. Martin-Vaca, N. Degrave, P. Demonchaux, O. Jentzer, D. Bourissou, and J. Siepmann PLGA microparticles with zero-order release of the labile anti-Parkinson drug apomorphine Int J Pharm 443 2013 68 79
195. A. Wang, L. Wang, K. Sun, W. Liu, C. Sha, and Y. Li Preparation of rotigotine-loaded microspheres and their combination use with l-DOPA to modify dyskinesias in 6-OHDA-lesioned rats Pharmaceut Res 29 2012 2367 2376
196. J. Tian, G. Du, L. Ye, X. Yu, J. Zhang, H. Wang, P. Yu, F. Fu, W. Liu, Y. Li, X. Cen, and X. Guan Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeys Food Chem Toxicol 52 2013 143 152
197. Y. Shen, S.I. Muramatsu, K. Ikeguchi, K.I. Fujimoto, D.S. Fan, M. Ogawa, H. Mizukami, M. Urabe, A. Kume, I. Nagatsu, F. Urano, T. Suzuki, H. Ichinose, T. Nagatsu, J. Monahan, I. Nakano, and K. Ozawa Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase aromatic-l-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease Hum Gene Ther 11 2000 1509 1519
198. S. Muramatsu, K. Fujimoto, K. Ikeguchi, N. Shizuma, K. Kawasaki, F. Ono, Y. Shen, L. Wang, H. Mizukami, A. Kume, M. Matsumura, I. Nagatsu, F. Urano, H. Ichinose, T. Nagatsu, K. Terao, I. Nakano, and K. Ozawa Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes Hum Gene Ther 13 2002 345 354
199. M. Azzouz, E. Martin-Rendon, R.D. Barber, K.A. Mitrophanous, E.E. Carter, J.B. Rohll, S.M. Kingsman, A.J. Kingsman, and N.D. Mazarakis Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic l-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease J Neurosci 22 2002 10302 10312
200. T. Björklund, T. Carlsson, E.A. Cederfjäll, M. Carta, and D. Kirik Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease Brain 133 2010 496 511
201. M. Fernández, E. Barcia, A. Fernández-Carballido, L. Garcia, K. Slowing, and S. Negro Controlled release of rasagiline mesylate promotes neuroprotection in a rotenone-induced advanced model of Parkinson's disease Int J Pharm 438 2012 266 278
202. R.T. Carroll, D. Bhatia, W. Geldenhuys, R. Bhatia, N. Miladore, A. Bishayee, and V. Sutariya Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders J Drug Target 18 2010 665 674
203. K. Hu, Y. Shi, W. Jiang, J. Han, S. Huang, and X. Jiang Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease Int J Pharm 415 2011 273 283
204. O. Boussif, F. Lezoualc'h, M.A. Zanta, M.D. Mergny, D. Scherman, B. Demeneix, and J.P. Behr A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine Proc Natl Acad Sci U S A 92 1995 7297 7301
205. B. Schwartz, C. Benoist, B. Abdallah, D. Scherman, J.P. Behr, and B.A. Demeneix Lipospermine-based gene transfer into the newborn mouse brain is optimized by a low lipospermine/DNA charge ratio Hum Gene Ther 6 1995 1515 1524
206. Y.T. Ko, R. Bhattacharya, and U. Bickel Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting J Control Release 133 2009 230 237
207. D. Martinez-Fong, M.J. Bannon, L.E. Trudeau, J.A. Gonzalez-Barrios, M.L. Arango-Rodriguez, N.G. Hernandez-Chan, D. Reyes-Corona, J. Armendáriz-Borunda, and I. Navarro-Quiroga NTS-polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease Nanomed Nanotechnol Biol Med 8 2012 1052 1069
208. J.A. Gonzalez-Barrios, M. Lindahl, M.J. Bannon, V. Anaya-Martinez, G. Flores, I. Navarro-Quiroga, L.E. Trudeau, J. Aceves, D.B. Martinez-Arguelles, R. Garcia-Villegas, I. Jimenez, J. Segovia, and D. Martinez-Fong Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats Mol Ther 14 2006 857 865
209. D.M. Yurek, A.M. Fletcher, G.M. Smith, K.B. Seroogy, A.G. Ziady, J. Molter, T.H. Kowalczyk, L. Padegimas, and M.J. Cooper Long-term transgene expression in the central nervous system using DNA nanoparticles Mol Ther 17 2009 641 650
210. A.M. Fletcher, T.H. Kowalczyk, L. Padegimas, M.J. Cooper, and D.M. Yurek Transgene expression in the striatum following intracerebral injections of DNA nanoparticles encoding for human glial cell line-derived neurotrophic factor Neuroscience 194 2011 220 226
211. R.W.P. Rodrigues, V.C. Gomide, and G. Chadi Astroglial and microglial activation in the wistar rat ventral tegmental area after a single injection of 6-hydroxydopamine Int J Neurosci 114 2004 197 216
212. B. Mirza, H. Hadberg, P. Thomsen, and T. Moos The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease Neuroscience 95 1999 425 432
213. G.D. Kenny, A.S. Bienemann, A.D. Tagalakis, J.A. Pugh, K. Welser, F. Campbell, A.B. Tabor, H.C. Hailes, S.S. Gill, M.F. Lythgoe, C.W. McLeod, E.A. White, and S.L. Hart Multifunctional receptor-targeted nanocomplexes for the delivery of therapeutic nucleic acids to the brain Biomaterials 34 2013 9190 9200
214. R. Huang, H. Ma, Y. Guo, S. Liu, Y. Kuang, K. Shao, J. Li, Y. Liu, L. Han, S. Huang, S. An, L. Ye, J. Lou, and C. Jiang Angiopep-conjugated nanoparticles for targeted long-term gene therapy of Parkinson's disease Pharmaceut Res 30 2013 2549 2559
215. P. Mulcahy, A. O'Doherty, A. Paucard, T. O'Brien, D. Kirik, and E. Dowd Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-α-synuclein and the pesticide, rotenone Neuroscience 203 2012 170 179
216. P. Kumar, H. Wu, J.L. McBride, K.E. Jung, M.H. Kim, B.L. Davidson, S.K. Lee, P. Shankar, and N. Manjunath Transvascular delivery of small interfering RNA to the central nervous system Nature 448 2007 39 43
217. R. Huang, W. Ke, Y. Liu, D. Wu, L. Feng, C. Jiang, and Y. Pei Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model J Neurol Sci 290 2010 123 130
218. R.Q. Huang, W.L. Ke, Y.H. Qu, J.H. Zhu, Y.Y. Pei, and C. Jiang Characterization of lactoferrin receptor in brain endothelial capillary cells and mouse brain J Biomed Sci 14 2007 121 128
219. C. Fillebeen, L. Descamps, M.P. Dehouck, L. Fenart, M. Benaïssa, G. Spik, R. Cecchelli, and A. Pierce Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier J Biol Chem 274 1999 7011 7017
220. R.J. Boado, and W.M. Pardridge The Trojan horse liposome technology for nonviral gene transfer across the blood-brain barrier J Drug Deliv 2011 296151/1-12
221. L. Alvarez-Erviti, Y. Seow, H. Yin, C. Betts, S. Lakhal, and M.J.A. Wood Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes Nat Biotechnol 29 2011 341 345
222. M.J. Wood, A.J. O'Loughlin, and L. Samira Exosomes and the blood-brain barrier: implications for neurological diseases Ther Deliv 2 2011 1095 1099
223. F. Verbaan, D. Crommelin, W. Hennink, and G. Storm Poly (2-(dimethylamino) ethyl methacrylate)-based polymers for the delivery of genes in vitro and in vivo M.M. Amiji, Polymeric gene delivery: principles and applications 2010 CRC Press, LLC Boca Raton, FL 116 151
224. L. Yao, W. Daly, B. Newland, S. Yao, W. Wang, B.K.K. Chen, N. Madigan, A. Windebank, and A. Pandit Improved axonal regeneration of transected spinal cord mediated by multichannel collagen conduits functionalized with neurotrophin-3 gene Gene Ther 20 2013 1149 1157
225. M.S. Rafii, T.L. Baumann, R.A.E. Bakay, J.M. Ostrove, J. Siffert, A.S. Fleisher, C.D. Herzog, D. Barba, M. Pay, D.P. Salmon, Y. Chu, J.H. Kordower, K. Bishop, D. Keator, S. Potkin, and R.T. Bartus A phase 1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease Alzheimer's Dement 10 2014 571 581
226. P.A. LeWitt, A.R. Rezai, M.A. Leehey, S.G. Ojemann, A.W. Flaherty, E.N. Eskandar, S.K. Kostyk, K. Thomas, A. Sarkar, M.S. Siddiqui, S.B. Tatter, J.M. Schwalb, K.L. Poston, J.M. Henderson, R.M. Kurlan, I.H. Richard, L. van Meter, C.V. Sapan, M.J. During, M.G. Kaplitt, and A. Feigin AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind sham-surgery controlled randomised trial Lancet Neurol 10 2011 309 319
227. W.J. Marks Jr., R.T. Bartus, J. Siffert, C.S. Davis, A. Lozano, N. Boulis, J. Vitek, M. Stacy, D. Turner, L. Verhagen, R. Bakay, R. Watts, B. Guthrie, J. Jankovic, R. Simpson, M. Tagliati, R. Alterman, M. Stern, G. Baltuch, P.A. Starr, P.S. Larson, J.L. Ostrem, J. Nutt, K. Kieburtz, J.H. Kordower, and C.W. Olanow Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomized, controlled trial Lancet Neurol 9 2010 1164 1172
228. S. Palfi, J.M. Gurruchaga, G.S. Ralph, H. Lepetit, S. Lavisse, P.C. Buttery, C. Watts, J. Miskin, M. Kelleher, S. Deeley, H. Iwamuro, J.P. Lefaucheur, C. Thiriez, G. Fenelon, C. Lucas, P. Brugières, I. Gabriel, K. Abhay, X. Drouot, N. Tani, A. Kas, B. Ghaleh, P. Le Corvoisier, P. Dolphin, D.P. Breen, S. Mason, N.V. Guzman, N.D. Mazarakis, P.A. Radcliffe, R. Harrop, S.M. Kingsman, O. Rascol, S. Naylor, R.A. Barker, P. Hantraye, P. Remy, P. Cesaro, and K.A. Mitrophanous Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial Lancet 383 2014 1138 1146
229. S.L. Ginn, I.E. Alexander, M.L. Edelstein, M.R. Abedi, and J. Wixon Gene therapy clinical trials worldwide to 2012 - an update J Gene Med 15 2013 65 77
230. M. Hutchinson At last, a gene therapy for Parkinson's disease? Lancet Neurol 10 2011 290 291
231. P.G. Coune, B.L. Schneider, and P. Aebischer Parkinson's disease: gene therapies Cold Spring Harb Perspect Med 2 2012 a009431/1-15
232. G. Modi, V. Pillay, Y.E. Choonara, V.M.K. Ndesendo, L.C. di Toit, and D. Naidoo Nanotechnological applications for the treatment of neurodegenerative disorders Prog Neurobiol 88 2009 272 285
233. C.A. Ross, and M.A. Poirier Protein aggregation and neurodegenerative disease Nat Med 10 2004 10 17
234. C. Cabaleiro-Lago, F. Quinlan-Pluck, I. Lynch, S. Lindman, A.M. Minogue, E. Thulin, D.M. Walsh, K.A. Dawson, and S. Linse Inhibition of amyloid β protein fibrillation by polymeric nanoparticles J Am Chem Soc 130 2008 15437 15443
235. S. Linse, C. Cabaleiro-Lago, W.F. Xue, I. Lynch, S. Lindman, E. Thulin, S.E. Radford, and K.A. Dawson Nucleation of protein fibrillation by nanoparticles Proc Natl Acad Sci U S A 104 2007 8691 8696
236. C. Cabaleiro-Lago, F. Quinlan-Pluck, I. Lynch, K.A. Dawson, and S. Linse Dual effect of amino modified polystyrene nanoparticles on amyloid β protein fibrillation ACS Chem Neurosci 1 2010 279 287
237. L. Breydo, J.W. Wu, and V.N. Uversky α-Synuclein misfolding and Parkinson's disease Biochim Biophys Acta 1822 2012 261 285
238. A. Rekas, V. Lo, G.E. Gadd, R. Cappai, and S.I. Yun PAMAM dendrimers as potential agents against fibrillation of α-synuclein, a Parkinson's disease-related protein Macromol Biosci 9 2009 230 238
239. K. Milowska, T. Gabryelak, M. Bryszewska, A.M. Caminade, and J.P. Majoral Phosphorus-containing dendrimers against α-synuclein fibril formation Int J Biol Macromol 50 2012 1138 1143
240. K. Milowska, J. Grochowina, N. Katir, A.E. Kadib, J.P. Majoral, M. Bryszewska, and T. Gabryelak Viologen-phosphorus dendrimers inhibit α-synuclein fibrillation Mol Pharm 10 2013 1131 1137
241. J. Goers, V.N. Uversky, and A.L. Fink Polycation-induced oligomerization and accelerated fibrillation of human α-synuclein in vitro Protein Sci 12 2003 702 707
242. X. Meng, L.A. Munishkina, A.L. Fink, and V.N. Uversky Effects of various flavonoids on the α-synuclein fibrillation process Parkinson's Dis 2010 650794/1-16
243. X. Meng, L.A. Munishkina, A.L. Fink, and V.N. Uversky Molecular mechanisms underlying the flavonoid-induced inhibition of α-synuclein fibrillation Biochemistry 48 2009 8206 8224
244. M. Zhu, S. Han, and A.L. Fink Oxidized quercetin inhibits α-synuclein fibrillization Biochim Biophys Acta 1830 2013 2872 2881
245. H.T. Li, D.H. Lin, X.Y. Luo, F. Zhang, L.N. Ji, H.N. Du, G.Q. Song, J. Hu, J.W. Zhou, and H.Y. Hu Inhibition of α-synuclein fibrillization by dopamine analogs via reaction with the amino groups of α-synuclein FEBS J 272 2005 3661 3672
246. J. Li, M. Zhu, A.B. Manning-Bog, D.A. Di Monte, and A.L. Fink Dopamine and l-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease FASEB J 18 2004 962 964
247. H. Zhang, L.P. Bré, T. Zhao, Y. Zheng, B. Newland, and W. Wang Mussel-inspired hyperbranched poly(amino ester) polymer as strong wet tissue adhesive Biomaterials 35 2014 711 719
248. O.T.W. Ng, Y. Wong, H.M. Chan, J. Cheng, X. Qi, W.H. Chan, K.K.L. Yung, and H.W. Li N-Acetyl-l-cysteine capped quantum dots offer neuronal cell protection by inhibiting beta (1-40) amyloid fibrillation Biomater Sci 1 2013 577 580
249. E. Salvati, F. Re, S. Sesana, I. Cambianica, G. Sancini, M. Masserini, and M. Gregori Liposomes functionalized to overcome the blood-brain barrier and to target amyloid-β peptide: the chemical design affects the permeability across an in vitro model Int J Nanomed 8 2013 1749
250. J.A. Cohlberg, J. Li, V.N. Uversky, and A.L. Fink Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from α-synuclein in vitro Biochemistry 41 2002 1502 1511
251. K.C. Luk, V. Kehm, J. Carroll, B. Zhang, P. O'Brien, J.Q. Trojanowski, and V.M.Y. Lee Pathological α-synuclein transmission initiates parkinson-like neurodegeneration in nontransgenic mice Science 338 2012 949 953
252. M. Masuda-Suzukake, T. Nonaka, M. Hosokawa, T. Oikawa, T. Arai, H. Akiyama, D.M.A. Mann, and M. Hasegawa Prion-like spreading of pathological α-synuclein in brain Brain 135 2013 1128 1138
253. M.J. Butte Neurotrophic factor structures reveal clues to evolution, binding, specificity, and receptor activation Cell Mol Life Sci 58 2001 1003 1013
254. M.M. Barbacid Neurotrophic factors and their receptors Curr Opin Cell Biol 7 1995 148 155
255. L. Lin, D. Doherty, J. Lile, S. Bektesh, and F. Collins GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons Science 260 1993 1130 1132
256. S.S. Gill, N.K. Patel, G.R. Hotton, K. O'Sullivan, R. McCarter, M. Bunnage, D.J. Brooks, C.N. Svendsen, and P. Heywood Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease Nat Med 9 2003 589 595
257. A.E. Lang, S. Gill, N.K. Patel, A. Lozano, J.G. Nutt, R. Penn, D.J. Brooks, G. Hotton, E. Moro, P. Heywood, M.A. Brodsky, K. Burchiel, P. Kelly, A. Dalvi, B. Scott, M. Stacy, D. Turner, V.G.F. Wooten, W.J. Elias, E.R. Laws, V. Dhawan, A.J. Stoessl, J. Matcham, R.J. Coffey, and M. Traub Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease Ann Neurol 59 2006 459 466
258. J.G. Nutt, K.J. Burchiel, C.L. Comella, J. Jankovic, A.E. Lang, E.R. Laws, A.M. Lozano, R.D. Penn, R.K. Simpson, M. Stacy, G.F. Wooten, and ICV GDNF Study Group Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD Neurology 60 2003 69 73
259. D.M. Gash, Z. Zhang, A. Ovadia, W.A. Cass, A. Yi, L. Simmerman, D. Russell, D. Martin, P.A. Lapchak, F. Collins, B.J. Hoffer, and G.A. Gerhard Functional recovery in parkinsonian monkeys treated with GDNF Nature 380 1996 252 255
260. A. Björklund, C. Rosenblad, C. Winkler, and D. Kirik Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease Neurobiol Dis 4 1997 186 200
261. Z. Zhang, Y. Miyoshi, P.A. Lapchak, F. Collins, D. Hilt, C. Lebel, R. Kryscio, and D.M. Gash Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys J Pharm Exp Ther 282 1997 1396 1401
262. T. Gill, N.U. Barua, M. Woolley, A.S. Bienemann, D.E. Johnson, S. O'Sullivan, G. Murray, C. Fennelly, O. Lewis, C. Irving, M.J. Wyatt, P. Moore, and S.S. Gill In vitro and in vivo testing of a novel recessed-step catheter for reflux-free convection-enhanced drug delivery to the brain J Neurosci Methods 219 2013 1 9
263. C.E. Krewson, M.L. Klarman, and W.M. Saltzman Distribution of nerve growth factor following direct delivery to brain interstitium Brain Res 680 1995 196 206
264. P. Menei, J.M. Pean, V. Nerrière-Daguin, C. Jollivet, P. Brachet, and J.P. Benoit Intracerebral implantation of NGF-releasing biodegradable microspheres protects striatum against excitotoxic damage Exp Neurol 161 2000 259 272
265. C. Gujral, Y. Minagawa, K. Fujimoto, H. Kitano, and T. Nakaji-Hirabayashi Biodegradable microparticles for strictly regulating the release of neurotrophic factors J Control Release 168 2013 307 316
266. N.B. Skop, F. Calderon, S.W. Levison, C.D. Gandhi, and C.H. Cho Heparin crosslinked chitosan microspheres for the delivery of neural stem cells and growth factors for central nervous system repair Acta Biomater 9 2013 6834 6843
267. F. Huang, Z. Yin, D. Wu, and J. Hao Effects of controlled release of brain-derived neurotrophic factor from collagen gel on rat neural stem cells Neuroreport 24 2013 101 107
268. S. Catrina, B. Gander, and S. Madduri Nerve conduit scaffolds for discrete delivery of two neurotrophic factors Eur J Pharm Biopharm 85 2013 139 142
269. S. Madduri, K. Feldman, T. Tervoort, M. Papaloïzos, and B. Gander Collagen nerve conduits releasing the neurotrophic factors GDNF and NGF J Control Release 143 2010 168 174
270. H. Kraskiewicz, B. Breen, T. Sargeant, S. McMahon, and A. Pandit Assembly of protein-based hollow spheres encapsulating a therapeutic factor ACS Chem Neurosci 4 2013 1297 1304
271. C. Gouhier, S. Chalon, A. Aubert-Pouessel, M.C. Venier-Julienne, C. Jollivet, J.P. Benoit, and D. Guilloteau Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease Synapse 44 2002 124 131
272. C. Jollivet, A. Aubert-Pouessel, A. Clavreul, M.C. Venier-Julienne, S. Remy, C.N. Montero-Menei, J.P. Benoit, and P. Menei Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease Biomaterials 25 2004 933 942
273. C. Jollivet, A. Aubert-Pouessel, A. Clavreul, M.C. Venier-Julienne, C.N. Montero-Menei, J.P. Benoit, and P. Menei Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease Neurosci Lett 356 2004 207 210
274. E. Garbayo, C.N. Montero-Menei, E. Ansorena, J.L. Lanciego, M.S. Aymerich, and M.J. Blanco-Prieto Effective GDNF brain delivery using microspheres - a promising strategy for Parkinson's disease J Control Release 135 2009 119 126
275. E. Garbayo, E. Ansorena, J.L. Lanciego, M.J. Blanco-Prieto, and M.S. Aymerich Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease Mov Disord 26 2011 1943 1947
276. T. Yasuhara, T. Shingo, K. Kobayashi, A. Takeuchi, A. Yano, K. Muraoka, T. Matsui, Y. Miyoshi, H. Hamada, and I. Date Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease Eur J Neurosci 19 2004 1494 1504
277. E. Herrán, J.Á. Ruiz-Ortega, A. Aristieta, M. Igartua, C. Requejo, J.V. Lafuente, L. Ugedo, J.L. Pedraz, and R.M. Hernández In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson's disease Eur J Pharm Biopharm 85 2013 1183 1190
278. E. Herrán, C. Requejo, J. Ruiz-Ortega, A. Aristieta, M. Igartua, H. Bengoetxea, L. Ugedo, J. Pedraz, J. Lafuente, and R. Hernández Increased antiparkinson efficacy of the combined administration of VEGF-and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease Int J Nanomed 9 2014 2677 2687
279. A. Quesada, B.Y. Lee, and P.E. Micevych PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease Dev Neurobiol 68 2008 632 644
280. A.D. Ebert, A.J. Beres, A.E. Barber, and C.N. Svendsen Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's disease Exp Neurol 209 2008 213 223
281. P. Lindholm, M.H. Voutilainen, J. Lauren, J. Peranen, V.M. Leppanen, J.O. Andressoo, M. Lindahl, S. Janhunen, N. Kalkkinen, T. Timmusk, R.K. Tuominen, and M. Saarma Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo Nature 448 2007 73 77
282. H. Takayama, J. Ray, H.K. Raymon, A. Baird, J. Hogg, L.J. Fisher, and F.H. Gage Basic fibroblast growth factor increases dopaminergic graft survival function in a rat model of Parkinson's disease Nat Med 1 1995 53 58
283. M.H. Voutilainen, S. Bäck, E. Pörsti, L. Toppinen, L. Lindgren, P. Lindholm, J. Peränen, M. Saarma, and R.K. Tuominen Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease J Neurosci 29 2009 9651 9659
284. S. Ferrati, D. Fine, J. You, E. De Rosa, L. Hudson, E. Zabre, S. Hosali, L. Zhang, C. Hickman, S.S. Bansal, A.M. Cordero-Reyes, T. Geninatti, J. Sih, R. Goodall, G. Palapattu, M. Kloc, R.M. Ghobrial, M. Ferrari, and A. Grattoni Leveraging nanochannels for universal, zero-order drug delivery in vivo J Control Release 172 2013 1011 1019
285. J. Wu, T. Kong, K.W.K. Yeung, H.C. Shum, K.M.C. Cheung, L. Wang, and M.K.T. To Fabrication and characterization of monodisperse PLGA-alginate core-shell microspheres with monodisperse size and homogeneous shells for controlled drug release Acta Biomater 9 2013 7410 7419
286. A. Agbay, N.K. Mohtaram, and S.M. Willerth Controlled release of glial cell line-derived neurotrophic factor from poly(É-caprolactone) microspheres Drug Deliv Transl Res 4 2014 159 170
287. K.J. Lampe, D.S. Kern, M.J. Mahoney, and K.B. Bjugstad The administration of BDNF and GDNF to the brain via PLGA microparticles patterned within a degradable PEG-based hydrogel: protein distribution and the glial response J Biomed Mater Res Part B 96 2011 595 607
288. R. Zietlow, E. Lane, S. Dunnett, and A. Rosser Human stem cells for CNS repair Cell Tissue Res 331 2008 301 322
289. A.K. Meyer, M. Maisel, A. Hermann, K. Stirl, and A. Storch Restorative approaches in Parkinson's disease: which cell type wins the race? J Neurol Sci 289 2010 93 103
290. K. Loewenbrück, and A. Storch Stem cell-based therapies in Parkinson's disease: future hope or current treatment option? J Neurol 258 2011 346 353
291. R.A. Barker, J. Barrett, S.L. Mason, and A. Björklund Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease Lancet Neurol 12 2013 84 91
292. V.H. Roberton, A.E. Evans, D.J. Harrison, S.V. Precious, S.B. Dunnett, C.M. Kelly, and A.E. Rosser Is the adult mouse striatum a hostile host for neural transplant survival? Neuroreport 24 2013 1010 1015
293. S.B. Dunnett, and A.E. Rosser Challenges for taking primary and stem cells into clinical neurotransplantation trials for neurodegenerative disease Neurobiol Dis 61 2014 79 89
294. H. Kim, M.J. Cooke, and M.S. Shoichet Creating permissive microenvironments for stem cell transplantation into the central nervous system Trends Biotechnol 30 2012 55 63
295. M.J. Cooke, K. Vulic, and M.S. Shoichet Design of biomaterials to enhance stem cell survival when transplanted into the damaged central nervous system Soft Matter 6 2010 4988 4998
296. G. Orive, E. Anitua, J.L. Pedraz, and D.F. Emerich Biomaterials for promoting brain protection, repair and regeneration Nat Rev Neurosci 10 2009 682 692
297. M.J. Mahoney, and W.M. Saltzman Transplantation of brain cells assembled around a programmable synthetic microenvironment Nat Biotechnol 19 2001 934 939
298. A. Clavreul, L. Sindji, A. Aubert-Pouëssel, J.P. Benoît, P. Menei, and C.N. Montero-Menei Effect of GDNF-releasing biodegradable microspheres on the function and the survival of intrastriatal fetal ventral mesencephalic cell grafts Eur J Pharm Biopharm 63 2006 221 228
299. V.M. Tatard, L. Sindji, J. Branton, A. Aubert-Pouëssel, J. Colleau, J.P. Benoit, and C.N. Montero-Menei Pharmacologically active microcarriers releasing glial cell line-derived neurotrophic factor: survival and differentiation of embryonic dopaminergic neurons after grafting in hemiparkinsonian rats Biomaterials 28 2007 1978 1988
300. G.J.R. Delcroix, E. Garbayo, L. Sindji, O. Thomas, C. Vanpouille-Box, P.C. Schiller, and C.N. Montero-Menei The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemi-parkinsonian rats Biomaterials 32 2011 1560 1573
301. J. Zhong, A. Chan, L. Morad, H.I. Kornblum, G. Fan, and S.T. Carmichael Hydrogel matrix to support stem cell survival after brain transplantation in stroke Neurorehabil Neural Repair 24 2010 636 644
302. T. Osanai, S. Kuroda, H. Yasuda, Y. Chiba, K. Maruichi, M. Hokari, T. Sugiyama, H. Shichinohe, and Y. Iwasaki Noninvasive transplantation of bone marrow stromal cells for ischemic stroke: preliminary study with a thermoreversible gelation polymer hydrogel Neurosurgery 66 2010 1140 1147
303. K. Jin, X. Mao, L. Xie, V. Galvan, B. Lai, Y. Wang, O. Gorostiza, X. Wang, and D.A. Greenberg Transplantation of human neural precursor cells in Matrigel scaffolding improves outcome from focal cerebral ischemia after delayed postischemic treatment in rats J Cereb Blood Flow Metab 30 2010 534 544
304. A. Mahmood, H. Wu, C. Qu, Y. Xiong, and M. Chopp Effects of treating traumatic brain injury with collagen scaffolds and human bone marrow stromal cells on sprouting of corticospinal tract axons into the denervated side of the spinal cord J Neurosurg 118 2013 381 389
305. N.B. Skop, F. Calderon, C.H. Cho, C.D. Gandhi, and S.W. Levison Optimizing a multifunctional microsphere scaffold to improve neural precursor cell transplantation for traumatic brain injury repair J Tissue Eng Regen Med 2013 10.1002/term.1832
306. W. Shi, D. Nie, G. Jin, W. Chen, L. Xia, X. Wu, X. Su, X. Xu, L. Ni, X. Zhang, X. Zhang, and J. Chen BDNF blended chitosan scaffolds for human umbilical cord MSC transplants in traumatic brain injury therapy Biomaterials 33 2012 3119 3126
307. T. Nakaji-Hirabayashi, K. Kato, and H. Iwata In vivo study on the survival of neural stem cells transplanted into the rat brain with a collagen hydrogel that incorporates laminin-derived polypeptides Bioconjugate Chem 24 2013 1798 1804
308. D.M. Yurek, A.M. Flectcher, T.H. Kowalczyk, L. Padegimas, and M.J. Cooper Compacted DNA nanoparticle gene transfer of GDNF to the rat striatum enhances the survival of grafted fetal dopamine neurons Cell Transpl 18 2009 1183 1196
309. M. Uemura, M.M. Refaat, M. Shinoyama, H. Hayashi, N. Hashimoto, and J. Takahashi Matrigel supports survival and neuronal differentiation of grafted embryonic stem cell-derived neural precursor cells J Neurosci Res 88 2010 542 551
310. T.Y. Wang, J.S. Forsythe, D.R. Nisbet, and C.L. Parish Promoting engraftment of transplanted neural stem cells/progenitors using biofunctionalised electrospun scaffolds Biomaterials 33 2012 9188 9197
311. T.Y. Cheng, M.H. Chen, W.H. Chang, M.Y. Huang, and T.W. Wang Neural stem cells encapsulated in a functionalized self-assembling peptide hydrogel for brain tissue engineering Biomaterials 34 2013 2005 2016
312. B.A. Aguado, W. Mulyasasmita, J. Su, K.J. Lampe, and S.C. Heilshorn Improving viability of stem cells during syringe needle flow through the design of hydrogel cell carriers Tissue Eng Part A 18 2011 806 815
313. K. Yang, J.S. Lee, J. Kim, Y.B. Lee, H. Shin, S.H. Um, J.B. Kim, K.I. Park, H. Lee, and S.W. Cho Polydopamine-mediated surface modification of scaffold materials for human neural stem cell engineering Biomaterials 33 2012 6952 6964
314. J.X. Xu, Z. Zhou, B. Wu, and B.F. He Enzymatic formation of a novel cell-adhesive hydrogel based on small peptides with a laterally grafted L-3,4-dihydroxyphenylalanine group Nanoscale 6 2014 1277 1280
315. W. Liu, Y. Li, Y. Zeng, X. Zhang, J. Wang, L. Xie, X. Li, and Y. Du Microcryogels as injectable 3-D cellular microniches for site-directed and augmented cell delivery Acta Biomater 10 2014 1864 1875
316. E. Tamariz, A.A. Wan, Y.S. Pek, M. Giordano, G. Hernández-Padrón, A. Varela-Echavarría, I. Velasco, and V. Castaño Delivery of chemotropic proteins and improvement of dopaminergic neuron outgrowth through a thixotropic hybrid nano-gel J Mater Sci Mater Med 22 2011 2097 2109
317. X. Li, E. Katsanevakis, X. Liu, N. Zhang, and X. Wen Engineering neural stem cell fates with hydrogel design for central nervous system regeneration Prog Polym Sci 37 2012 1105 1129
318. S. Uchida, K. Itaka, T. Nomoto, T. Endo, Y. Matsumoto, T. Ishii, and K. Kataoka An injectable spheroid system with genetic modification for cell transplantation therapy Biomaterials 35 2014 2499 2506
319. M.M. Nashatizadeh, K.E. Lyons, and R. Pahwa A review of ropinirole prolonged release in Parkinson's disease Clin Interv Aging 4 2009 179 186
320. C.W. Olanow, K. Kieburtz, P. Odin, A.J. Espay, D.G. Standaert, H.H. Fernandez, A. Vanagunas, A.A. Othman, K.L. Widnell, W.Z. Robieson, Y. Pritchett, K. Chatamra, J. Benesh, R.A. Lenz, and A. Antonini Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised controlled, double-blind, double-dummy study Lancet Neurol 13 2014 141 149
321. R.T. Bartus, T.L. Baumann, L. Brown, B.R. Kruegel, J.M. Ostrove, and C.D. Herzog Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's disease Neurobiol Aging 34 2013 35 61
322. R.J. Mandel CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease Curr Opin Mol Ther 12 2010 240 247
323. T. Zhao, H. Zhang, B. Newland, A. Aied, D. Zhou, and W. Wang Significance of branching for transfection: synthesis of highly branched degradable functional poly(dimethylaminoethyl methacrylate) by vinyl oligomer combination Angew Chem Int Ed 53 2014 6095 6100
324. H. Yin, R.L. Kanasty, A.A. Eltoukhy, A.J. Vegas, J.R. Dorkin, and D.G. Anderson Non-viral vectors for gene-based therapy Nat Rev Genet 15 2014 541 555
325. E.H. Nafea, A. Marson, L.A. Poole-Warren, and P.J. Martens Immunoisolating semi-permeable membranes for cell encapsulation: focus on hydrogels J Control Release 154 2011 110 122
326. L. Fjord-Larsen, P. Kusk, J. Tornoe, B. Juliusson, M. Torp, C.R. Bjarkam, M.S. Nielsen, A. Handberg, J.C.H. Sorensen, and L.U. Wahlberg Long-term delivery of nerve growth factor by encapsulated cell biodelivery in the Gottingen minipig basal forebrain Mol Ther 18 2010 2164 2172
327. P. Aebischer, S.R. Winn, P.A. Tresco, C.B. Jaeger, and L.A. Greene Transplantation of polymer encapsulated neurotransmitter secreting cells: effect of the encapsulation technique J Biomech Eng 113 1991 178 183
328. O. Lindvall, and L.U. Wahlberg Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease? Exp Neurol 209 2008 82 88
329. J. Bloch, A. Bachoud-Levi, N. Deglon, J. Lefaucheur, L. Winkel, S. Palfi, J. Nguyen, C. Bourdet, P. Remy, and P. Brugières Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study Hum Gene Ther 15 2004 968 975
330. D.M. Marchionini, T.J. Collier, M. Camargo, S. McGuire, M. Pitzer, and C.E. Sortwell Interference with anoikis-induced cell death of dopamine neurons: implications for augmenting embryonic graft survival in a rat model of Parkinson's disease J Comp Neurol 464 2003 172 179